SCM
OKUR

Stonepine Capital Management’s OnKure Therapeutics OKUR Stock Holding History

Stonepine Capital Management’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$596K Sell
130,684
-1,894
-1% -$8.13K 0.34% 60
2026
Q1 		$549K Buy
+132,578
New +$409K 0.22% 55

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stonepine Capital Management's OKUR Position: Q2 2026 in Review

Stonepine Capital Management reduced its OnKure Therapeutics (OKUR) stake by 1.4% in Q2 2026, selling an estimated $8.13K and leaving 130,684 shares worth $596K. The position accounts for 0.34% of the portfolio, ranked #60.

Stonepine Capital Management first reported a position in OKUR in Q1 2026 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Stonepine Capital Management held 130,684 shares of OnKure Therapeutics worth $596K as of Q2 2026.
  • Stonepine Capital Management sold 1,894 OnKure Therapeutics shares in Q2 2026, an estimated $8.13K.
  • OnKure Therapeutics made up 0.34% of Stonepine Capital Management's portfolio in Q2 2026, its #60 holding.
  • Stonepine Capital Management first reported a position in OnKure Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.